In this video, Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, briefly discusses the role of bispecifics in Hodgkin lymphoma (HL), highlighting promising agents in the pipeline, such as AFM13, and the importance of further evaluating these agents in clinical trials. This interview took place at The 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Research funding from Seattle Genetics, BMS, Affimed, Regeneron, Takeda, AstraZeneca, Pfizer, ADC Therapeutics to my institution for clinical trials.